JNJ-90189892

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-90189892, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms [Phase 1]